Also trades as: NRSN (NASDAQ) · $vol 0M
NRSNW NASDAQ
NeuroSense Therapeutics Ltd.
1W: -42.9%
1M: -61.5%
3M: -60.0%
YTD: -73.4%
1Y: -60.0%
3Y: -77.0%
$0.08
+0.00 (+0.62%)
Weekly Expected Move ±63.0%
$-0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.0M
52W Range0.0805-0.3
Volume2,429
Avg Volume2,420
Beta1.58
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAlon Ben-Noon
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-09
Websiteneurosense-tx.com
Medinat ha-Yehudim Street 85
Herzliya 4676670
IL
Herzliya 4676670
IL
972 9 953 1142
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Latest News
NeuroSense Announces Pricing of Insider-Led PIPE Financing
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Up 21.3% in March
Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50
NeuroSense Therapeutics receives Nasdaq notices over listing requirements
Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Eisenberg Or | A-Award | 200,000 | — | 2026-03-26 |
| Russek-Blum Niva | A-Award | 200,000 | — | 2026-03-26 |
| Binder Hagit | A-Award | 200,000 | — | 2026-03-26 |
| Eisenberg Or | 0 | — | 2026-03-18 | |
| Eisenberg Or | 0 | — | 2026-03-18 |